Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Salivary gland tumors: Treatment of locoregional disease

William M Lydiatt, MD
Jeanne M Quivey, MD, FACR
Section Editors
Bruce E Brockstein, MD
David M Brizel, MD
Daniel G Deschler, MD, FACS
Marvin P Fried, MD, FACS
Deputy Editor
Michael E Ross, MD


Salivary gland tumors include a wide range of tumor types, which can be either benign or malignant (table 1). Approximately 85 percent arise in the parotid; the remainder originate in the submandibular, sublingual, and minor salivary glands, which are located throughout the submucosa of the mouth and upper aerodigestive tract (figure 1) [1]. Approximately 25 percent of parotid tumors are malignant, compared with 40 to 45 percent of submandibular gland tumors, 70 to 90 percent of sublingual gland tumors, and 50 to 75 percent of minor salivary gland tumors.

Treatment recommendations are based upon retrospective reviews of clinical experience, and there are almost no data from randomized trials to guide treatment decisions. The published literature predominately focuses on the parotid gland, reflecting the relative frequency of parotid gland tumors compared with tumors at other sites. The treatment of locoregional disease, which includes stages I through IVB (table 2A-B), will be discussed here.

Other topics on salivary gland tumors include:

(See "Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging".)

(See "Malignant salivary gland tumors: Treatment of recurrent and metastatic disease".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Dec 07, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Guzzo M, Locati LD, Prott FJ, et al. Major and minor salivary gland tumors. Crit Rev Oncol Hematol 2010; 74:134.
  2. NCCN guidelines http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.
  3. Lam KH, Wei WI, Ho HC, Ho CM. Whole organ sectioning of mixed parotid tumors. Am J Surg 1990; 160:377.
  4. O'Brien CJ. Current management of benign parotid tumors--the role of limited superficial parotidectomy. Head Neck 2003; 25:946.
  5. Lim YC, Lee SY, Kim K, et al. Conservative parotidectomy for the treatment of parotid cancers. Oral Oncol 2005; 41:1021.
  6. Hussain A, Murray DP. Preservation of the superficial lobe for deep-lobe parotid tumors: a better aesthetic outcome. Ear Nose Throat J 2005; 84:518, 520.
  7. Roh JL, Park CI. Function-preserving parotid surgery for benign tumors involving the deep parotid lobe. J Surg Oncol 2008; 98:42.
  8. Helmus C. Subtotal parotidectomy: a 10-year review (1985 to 1994). Laryngoscope 1997; 107:1024.
  9. Leverstein H, van der Wal JE, Tiwari RM, et al. Surgical management of 246 previously untreated pleomorphic adenomas of the parotid gland. Br J Surg 1997; 84:399.
  10. Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 1986; 8:177.
  11. Guntinas-Lichius O, Appenrodt S, Veelken F, Krug B. Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer. Laryngoscope 2006; 116:613.
  12. Laccourreye H, Laccourreye O, Cauchois R, et al. Total conservative parotidectomy for primary benign pleomorphic adenoma of the parotid gland: a 25-year experience with 229 patients. Laryngoscope 1994; 104:1487.
  13. McGurk M, Renehan A, Gleave EN, Hancock BD. Clinical significance of the tumour capsule in the treatment of parotid pleomorphic adenomas. Br J Surg 1996; 83:1747.
  14. Wennmo C, Spandow O, Emgård P, Krouthén B. Pleomorphic adenomas of the parotid gland: superficial parotidectomy or limited excision? J Laryngol Otol 1988; 102:603.
  15. Guntinas-Lichius O, Klussmann JP, Schroeder U, et al. Primary parotid malignoma surgery in patients with normal preoperative facial nerve function: outcome and long-term postoperative facial nerve function. Laryngoscope 2004; 114:949.
  16. Terhaard C, Lubsen H, Tan B, et al. Facial nerve function in carcinoma of the parotid gland. Eur J Cancer 2006; 42:2744.
  17. Sullivan MJ, Breslin K, McClatchey KD, et al. Malignant parotid gland tumors: a retrospective study. Otolaryngol Head Neck Surg 1987; 97:529.
  18. Kimata Y, Sakuraba M, Hishinuma S, et al. Free vascularized nerve grafting for immediate facial nerve reconstruction. Laryngoscope 2005; 115:331.
  19. Meier JD, Wenig BL, Manders EC, Nenonene EK. Continuous intraoperative facial nerve monitoring in predicting postoperative injury during parotidectomy. Laryngoscope 2006; 116:1569.
  20. Eisele DW, Wang SJ, Orloff LA. Electrophysiologic facial nerve monitoring during parotidectomy. Head Neck 2010; 32:399.
  21. Scianna JM, Petruzzelli GJ. Contemporary management of tumors of the salivary glands. Curr Oncol Rep 2007; 9:134.
  22. Nouraei SA, Ismail Y, Ferguson MS, et al. Analysis of complications following surgical treatment of benign parotid disease. ANZ J Surg 2008; 78:134.
  23. de Bree R, van der Waal I, Leemans CR. Management of Frey syndrome. Head Neck 2007; 29:773.
  24. Dulguerov P, Quinodoz D, Cosendai G, et al. Frey syndrome treatment with botulinum toxin. Otolaryngol Head Neck Surg 2000; 122:821.
  25. de Bree R, Duyndam JE, Kuik DJ, Leemans CR. Repeated botulinum toxin type A injections to treat patients with Frey syndrome. Arch Otolaryngol Head Neck Surg 2009; 135:287.
  26. Sanabria A, Kowalski LP, Bradley PJ, et al. Sternocleidomastoid muscle flap in preventing Frey's syndrome after parotidectomy: a systematic review. Head Neck 2012; 34:589.
  27. Ryan WR, Fee WE. Long-term great auricular nerve morbidity after sacrifice during parotidectomy. Laryngoscope 2009; 119:1140.
  28. Linkov G, Morris LG, Shah JP, Kraus DH. First bite syndrome: incidence, risk factors, treatment, and outcomes. Laryngoscope 2012; 122:1773.
  29. Ichimura K, Nibu K, Tanaka T. Nerve paralysis after surgery in the submandibular triangle: review of University of Tokyo Hospital experience. Head Neck 1997; 19:48.
  30. Berini-Aytes L, Gay-Escoda C. Morbidity associated with removal of the submandibular gland. J Craniomaxillofac Surg 1992; 20:216.
  31. Hong KH, Kim YK. Intraoral removal of the submandibular gland: a new surgical approach. Otolaryngol Head Neck Surg 2000; 122:798.
  32. Torroni AA, Mustazza MC, Bartoli DD, Iannetti GG. Transcervical submandibular sialoadenectomy. J Craniofac Surg 2007; 18:613.
  33. Baek CH, Jeong HS. Endoscope-assisted submandibular sialadenectomy: a new minimally invasive approach to the submandibular gland. Am J Otolaryngol 2006; 27:306.
  34. Hong KH, Yang YS. Surgical results of the intraoral removal of the submandibular gland. Otolaryngol Head Neck Surg 2008; 139:530.
  35. Kaszuba SM, Zafereo ME, Rosenthal DI, et al. Effect of initial treatment on disease outcome for patients with submandibular gland carcinoma. Arch Otolaryngol Head Neck Surg 2007; 133:546.
  36. Yu T, Gao QH, Wang XY, et al. Malignant sublingual gland tumors: a retrospective clinicopathologic study of 28 cases. Oncology 2007; 72:39.
  37. Perez DE, Pires FR, Alves Fde A, et al. Sublingual salivary gland tumors: clinicopathologic study of six cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100:449.
  38. Rinaldo A, Shaha AR, Pellitteri PK, et al. Management of malignant sublingual salivary gland tumors. Oral Oncol 2004; 40:2.
  39. Parsons JT, Mendenhall WM, Stringer SP, et al. Management of minor salivary gland carcinomas. Int J Radiat Oncol Biol Phys 1996; 35:443.
  40. Bell RB, Dierks EJ, Homer L, Potter BE. Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg 2005; 63:917.
  41. Chou C, Zhu G, Luo M, Xue G. Carcinoma of the minor salivary glands: results of surgery and combined therapy. J Oral Maxillofac Surg 1996; 54:448.
  42. Cianchetti M, Sandow PS, Scarborough LD, et al. Radiation therapy for minor salivary gland carcinoma. Laryngoscope 2009; 119:1334.
  43. Armstrong JG, Harrison LB, Thaler HT, et al. The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer 1992; 69:615.
  44. Kelley DJ, Spiro RH. Management of the neck in parotid carcinoma. Am J Surg 1996; 172:695.
  45. Terhaard CH, Lubsen H, Rasch CR, et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 2005; 61:103.
  46. Stennert E, Kisner D, Jungehuelsing M, et al. High incidence of lymph node metastasis in major salivary gland cancer. Arch Otolaryngol Head Neck Surg 2003; 129:720.
  47. Zbären P, Schüpbach J, Nuyens M, et al. Carcinoma of the parotid gland. Am J Surg 2003; 186:57.
  48. Zbären P, Schüpbach J, Nuyens M, Stauffer E. Elective neck dissection versus observation in primary parotid carcinoma. Otolaryngol Head Neck Surg 2005; 132:387.
  49. Chen AM, Garcia J, Lee NY, et al. Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: what is the role of elective neck irradiation? Int J Radiat Oncol Biol Phys 2007; 67:988.
  50. Schramm VL Jr, Imola MJ. Management of nasopharyngeal salivary gland malignancy. Laryngoscope 2001; 111:1533.
  51. Mendenhall WM, Morris CG, Amdur RJ, et al. Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer 2005; 103:2544.
  52. Armstrong JG, Harrison LB, Spiro RH, et al. Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg 1990; 116:290.
  53. Al-Mamgani A, van Rooij P, Verduijn GM, et al. Long-term outcomes and quality of life of 186 patients with primary parotid carcinoma treated with surgery and radiotherapy at the Daniel den Hoed Cancer Center. Int J Radiat Oncol Biol Phys 2012; 84:189.
  54. Mahmood U, Koshy M, Goloubeva O, Suntharalingam M. Adjuvant radiation therapy for high-grade and/or locally advanced major salivary gland tumors. Arch Otolaryngol Head Neck Surg 2011; 137:1025.
  55. Ghosh-Laskar S, Murthy V, Wadasadawala T, et al. Mucoepidermoid carcinoma of the parotid gland: factors affecting outcome. Head Neck 2011; 33:497.
  56. Chen AM, Bucci MK, Weinberg V, et al. Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence. Int J Radiat Oncol Biol Phys 2006; 66:152.
  57. Mendenhall WM, Morris CG, Amdur RJ, et al. Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck 2004; 26:154.
  58. Dillon PM, Chakraborty S, Moskaluk CA, et al. Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials. Head Neck 2016; 38:620.
  59. Amini A, Waxweiler TV, Brower JV, et al. Association of Adjuvant Chemoradiotherapy vs Radiotherapy Alone With Survival in Patients With Resected Major Salivary Gland Carcinoma: Data From the National Cancer Data Base. JAMA Otolaryngol Head Neck Surg 2016; 142:1100.
  60. Chen AM, Bucci MK, Quivey JM, et al. Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int J Radiat Oncol Biol Phys 2006; 66:1044.
  61. Wang CC, Goodman M. Photon irradiation of unresectable carcinomas of salivary glands. Int J Radiat Oncol Biol Phys 1991; 21:569.
  62. Romesser PB, Cahlon O, Scher E, et al. Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. Radiother Oncol 2016; 118:286.
  63. Laramore GE, Krall JM, Griffin TW, et al. Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys 1993; 27:235.
  64. Douglas JG, Koh WJ, Austin-Seymour M, Laramore GE. Treatment of salivary gland neoplasms with fast neutron radiotherapy. Arch Otolaryngol Head Neck Surg 2003; 129:944.
  65. Jensen AD, Nikoghosyan AV, Lossner K, et al. COSMIC: A Regimen of Intensity Modulated Radiation Therapy Plus Dose-Escalated, Raster-Scanned Carbon Ion Boost for Malignant Salivary Gland Tumors: Results of the Prospective Phase 2 Trial. Int J Radiat Oncol Biol Phys 2015; 93:37.
  66. Witt RL. The significance of the margin in parotid surgery for pleomorphic adenoma. Laryngoscope 2002; 112:2141.
  67. Harney M, Walsh P, Conlon B, et al. Parotid gland surgery: a retrospective review of 108 cases. J Laryngol Otol 2002; 116:285.
  68. Mendenhall WM, Mendenhall CM, Werning JW, et al. Salivary gland pleomorphic adenoma. Am J Clin Oncol 2008; 31:95.
  69. Witt RL. Minimally invasive surgery for parotid pleomorphic adenoma. Ear Nose Throat J 2005; 84:308, 310.
  70. Liu FF, Rotstein L, Davison AJ, et al. Benign parotid adenomas: a review of the Princess Margaret Hospital experience. Head Neck 1995; 17:177.
  71. Nouraei SA, Ferguson MS, Clarke PM, et al. Metastasizing pleomorphic salivary adenoma. Arch Otolaryngol Head Neck Surg 2006; 132:788.
  72. Chen AM, Garcia J, Bucci MK, et al. Recurrent pleomorphic adenoma of the parotid gland: long-term outcome of patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006; 66:1031.
  73. Myssiorek D, Ruah CB, Hybels RL. Recurrent pleomorphic adenomas of the parotid gland. Head Neck 1990; 12:332.
  74. Ravasz LA, Terhaard CH, Hordijk GJ. Radiotherapy in epithelial tumors of the parotid gland: case presentation and literature review. Int J Radiat Oncol Biol Phys 1990; 19:55.
  75. Leonetti JP, Marzo SJ, Petruzzelli GJ, Herr B. Recurrent pleomorphic adenoma of the parotid gland. Otolaryngol Head Neck Surg 2005; 133:319.
  76. Hocwald E, Korkmaz H, Yoo GH, et al. Prognostic factors in major salivary gland cancer. Laryngoscope 2001; 111:1434.
  77. Roh JL, Choi SH, Lee SW, et al. Carcinomas arising in the submandibular gland: high propensity for systemic failure. J Surg Oncol 2008; 97:533.
  78. Vander Poorten VL, Balm AJ, Hilgers FJ, et al. Prognostic factors for long term results of the treatment of patients with malignant submandibular gland tumors. Cancer 1999; 85:2255.
  79. Pedersen D, Overgaard J, Søgaard H, et al. Malignant parotid tumors in 110 consecutive patients: treatment results and prognosis. Laryngoscope 1992; 102:1064.
  80. Vander Poorten VL, Balm AJ, Hilgers FJ, et al. The development of a prognostic score for patients with parotid carcinoma. Cancer 1999; 85:2057.
  81. Carrillo JF, Vázquez R, Ramírez-Ortega MC, et al. Multivariate prediction of the probability of recurrence in patients with carcinoma of the parotid gland. Cancer 2007; 109:2043.
  82. Spiro RH, Thaler HT, Hicks WF, et al. The importance of clinical staging of minor salivary gland carcinoma. Am J Surg 1991; 162:330.
  83. Le QT, Birdwell S, Terris DJ, et al. Postoperative irradiation of minor salivary gland malignancies of the head and neck. Radiother Oncol 1999; 52:165.
  84. Poulsen MG, Pratt GR, Kynaston B, Tripcony LB. Prognostic variables in malignant epithelial tumors of the parotid. Int J Radiat Oncol Biol Phys 1992; 23:327.
  85. Garden AS, Weber RS, Morrison WH, et al. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys 1995; 32:619.
  86. Lopes MA, Santos GC, Kowalski LP. Multivariate survival analysis of 128 cases of oral cavity minor salivary gland carcinomas. Head Neck 1998; 20:699.
  87. Gao M, Hao Y, Huang MX, et al. Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma. Int J Oral Maxillofac Surg 2013; 42:923.